Oct 17, 2002|
Ranbaxy: 'Ceftin' kicker
Ranbaxy Laboratories has reported consolidated revenues of Rs 10.4 bn (US$ 216 m) for 3QFY03, which is in line with market expectations. On a stand alone basis, the company has reported a growth of 55% in revenues (including other operational income). Though there has been margin expansion, it is slightly lower than our expectations. We maintain our FY03 EPS estimate of Rs 31 on consolidated basis for the company.
|Operating Profit (EBDIT)
|Operating Profit Margin (%)
|Profit before Tax
|Profit after Tax/(Loss)
|Net profit margin (%)
|No. of Shares (eoy) (m)
|Diluted Earnings per share*
|P/E (at current price)
The highlight of the quarterly results was the strong performance recorded by Ranbaxy in the US markets. The US subsidiary of the company recorded 216% topline growth for the quarter. US markets now contribute 35% of the global (consolidated) sales of the company surpassing the contribution from the domestic markets (30%). While formulation exports grew by more than 150%, bulk exports were down 4%. The growth in formulation exports was driven primarily by anti-infective, Cefuroxime Axetil (Ceftin), which contributed approximately US$ 37 m (Rs 1.8 bn) to export sales.
It may be recalled that due to lack of any other player in the market with necessary approvals, Ranbaxy continues to enjoy ‘technical’ monopoly (in generic version) for marketing anti-infective, Cefuroxime Axetil (Ceftin) in the US markets. The company launched the drug in March this year and already enjoyed more than 7 months of exclusivity on the US$ 400 m drug and this exclusivity is likely to continue at least for another 6 months. Apotex, the nearest generic competitor of Ranbaxy recently received the US FDA approval for its ANDA of Cefuroxime Axetil (only for certain dosages).
However, Apotex is unlikely to launch its product due to its pending litigation on patent infringement and marketing injunction filed by original patent holder Glaxo. Apotex is unlikely to enter the market before the end of December this year. Ranbaxy would thus be able to catch up with the peak season sales of the drug, which usually starts from September. Ranbaxy is thus likely to continue with its monopoly status for another 3-5 months. Even after Apotex entry, third generic player is expected only after July'03 and hence the drop in pricing of the drug may not be drastic. Ranbaxy mopped up US$ 38 m of 'Ceftin' sales during the September quarter. The company currently enjoys more than 87% market share of the product. Till date the company has already earned US$ 75 m since its 'Ceftin' launch in March this year. We had earlier expected sales from Cefuroxime Axetil (Ceftin) to touch US$ 90 m in the current year, which needs to be revised upwards considering the extended exclusivity enjoyed by the company.
Ranbaxy (standalone) Revenue Mix- Exports led performance
The performance in the domestic market was however lackluster, primarily on account of 43% negative growth recorded by the company in the bulk drug business. This was due to planned reduction on account of increasing requirements to meet its internal formulation sales and also on account of giving preference to bulk exports vis'-a-vis' domestic market. There has also been apparent drop in growth in domestic formulations business not keeping pace with the industry growth rates. It may be mentioned over here that the company has recently commenced a new Consumer Healthcare division to focus on the fast growing OTC segment in the domestic and international markets. This division is expected to start contributing to revenues from the next quarter.
The research spend of the company is steadily inching ahead, representing more than 6% of the company's sales. Ranbaxy recently received approval for conducting clinical trials for its new anti-asthma molecule in India, for which the company might look at outsourcing opportunities. It was only recently that the company signed an agreement to out-license its lead R&D molecule (RBX-2258) for the treatment of Benign Prostrate Hyperplasia (BPH) to Schwarz Pharma of Germany. The 500 mg Cipro-D molecule licensed to Bayer AG has completed its clinical trials and Bayer has filed an NDA (New Drug Application). It may be noted that following approval from the authorities, it would reach the commercialisation stage. This could trigger a considerable milestone payment for Ranbaxy. Considering the time taken by regulatory authorities for approval, we expect launch of Cipro-D by mid-2003, ahead of original Ciprofloxacin patent expiry in 2003 end.
Consolidated Results Snapshot
|Operating Margins (%)
Ranbaxy has ramped up its product approvals in last few months for the international markets. The latest one being generic manufacturing and marketing approval for all combinations of Lisinopril drug, which is a multi-billion cardiovascular molecule. The company currently has a basket of 50+ products for the US markets now, far ahead of any other Indian generic company. As mentioned earlier, the US geography recorded 217% growth for 3QFY03. Even excluding Ceftin sales, formulations sales in the US registered an impressive 69% growth for the first half of the current year. European sales growth was also encouraging at 36%. There has been a sharp improvement in the global performance of the company for the second quarter as is evident from the above table. The company's targeted penetration in Germany, Brazil and UK seems to be working well.
At the current market price of Rs 565, the stock is trading at 18x FY03E earnings on a consolidated basis. Considering rapid ANDA (Abbreviated New Drug Applications) and expanding export portfolio of the company, Ranbaxy clearly has well laid out infrastructure to lead the lucrative generic opportunity.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
May 30, 2017
US markets decline while other geographies grow in the quarter.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
TRACK RANBAXY LAB
- Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks